SCHEMBL6254584

SCHEMBL6254584

CC(C)(C)OC(=O)N[C@@H](Cc1ncc(-c2ccccc2)o1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPPA P01160 3/20 0.54
MME P08473 3/20 0.54
ACE P12821 1/20 0.51
PPARA Q07869 5/20 0.47
PPARG P37231 4/20 0.47
PTPN1 P18031 3/20 0.46
ITGB3 P05106 1/20 0.46
ITGA2B P08514 1/20 0.46
NOTUM Q6P988 1/20 0.46
RXRA P19793 1/20 0.45
RXRB P28702 1/20 0.45
RXRG P48443 1/20 0.45
CTSS P25774 3/20 0.45
PPARD Q03181 2/20 0.45
CTSK P43235 2/20 0.45
CTSL P07711 1/20 0.45
CTSB P07858 1/20 0.45
ITGA4 P13612 1/20 0.45
ITGB7 P26010 1/20 0.45
SCN9A Q15858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6259306 0.87 PPARA (0.47) ACEPPARACTSSCTSKCTSL
SCHEMBL6807219 0.83 SYK (0.47) NPPAMMEITGB3ITGA2BCTSS
SCHEMBL23295686 0.82 ITGB3 (0.46) ACEPPARAPPARGPTPN1ITGB3
SCHEMBL23295688 0.82 ITGB3 (0.46) ACEPPARAPPARGPTPN1ITGB3
SCHEMBL6254719 0.82 NPPA (0.52) NPPAMMEITGB3ITGA2BCTSS
SCHEMBL8325469 0.79 NOTUM (0.48) NPPAMMENOTUMRXRARXRB
SCHEMBL28969031 0.77 NPPA (0.47) NPPAMMEPPARAITGB3ITGA2B
SCHEMBL28968928 0.77 NPPA (0.47) NPPAMMEPPARAITGB3ITGA2B
SCHEMBL606309 0.76 ACE (0.79) ACEPPARAPPARGPTPN1ITGB3
SCHEMBL66220 0.76 ACE (0.79) ACEPPARAPPARGPTPN1ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578735-A1 CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS Pfizer Limited (GB) 2005-09-28 EP disclosed
US-20040138274-A1 Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders DACK KEVIN NEIL (GB) 2004-07-15 US disclosed
WO-2004056787-A1 CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS PFIZER LIMITED (GB) 2004-07-08 WO disclosed
WO-2004056787-A1 CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS PFIZER LIMITED (GB) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138274-A1 Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders MME, ECE1, ECE2 NPPA 53/4885MME 1/4885ACE 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.